?> Contact us Follow Us
Biosimilars Forum
  • About Us
    • Members
    • Executive Director
  • Why Biosimilars
    • The Issue
    • Our Solutions
  • Biosimilars 101
    • Foundations
    • Core Principles
    • FDA Regulatory Tenets
    • Biosimilars FAQs
    • Future Evolution of Biosimilar Development
    • Approved Biosimilars
  • Advocacy
    • Our Action
    • Tools
  • News
  • Resources
  • Get Involved
    • Partners

Archives: Resources

Get more out of your business.
Reach it with Microsoft Dynamics 365 Business Central.
March 15, 2024 signalgroup
Letter of Support for PBM Reform
November 3, 2023 signalgroup
Setting the Record Straight on Biosimilar Interchangeability
November 1, 2023 signalgroup
Transitioning from a Reference Biologic to a Biosimilar is Safe and Effective
August 24, 2023 signalgroup
Biosimilars: Non-Medical Switching and Transitioning
August 7, 2023 signalgroup
Streamlining Biosimilar Development: The Developer’s Perspective One-Pager
April 5, 2023 signalgroup
Biosimilars Forum Comments on BsUFA III Research Roadmap
December 20, 2022 signalgroup
Shared Savings Programs in Europe
October 4, 2022 signalgroup
Inflation Reduction Act – ASP+8 Biosimilars Payment Increase
September 26, 2022 signalgroup
Biosimilars: Non-Medical Switching and Transitioning
August 3, 2022 signalgroup
Humira® Biosimilars: Reaching the Market’s Cost-Savings Potential
  • 01
  • 02
  • 03
  • 04

  • Biosimilars 101
  • Biosimilars FAQs
  • Advocacy
  • Stay Connected
Biosimilars Forum
© 2025 Biosimilars Forum. All rights reserved.
  • Terms of Use
  • |
  • Privacy Policy
  • |
  • Contact Us